To ask the Secretary of State for Health and Social Care, what steps Public Health England plans to take to assess the effectiveness of the HPV vaccination programme.
12 March 2020
Public Health England (PHE) is conducting surveillance activities to monitor the effectiveness of the National Human Papillomavirus (HPV) Vaccination Programme. The current HPV vaccine protects against two high-risk HPV types, HPV16 and HPV18 which cause around 80% of cervical cancers in the United Kingdom and two low-risk HPV types, HPV6 and HPV11 which cause most genital warts.
Surveillance conducted among young sexually active women in England has compared changes in the number of women who have a HPV infection over time since the introduction of the HPV vaccination.